Active, not recruitingPhase 2NCT04030559
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Studying Ataxia-telangiectasia variant
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Marc Dall'Era, MD
- Principal Investigator
- Marc Dall'EraUniversity of California, Davis
- Intervention
- Niraparib(drug)
- Enrollment
- 11 target
- Eligibility
- 18 years · MALE
- Timeline
- 2020 – 2025
Study locations (1)
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Collaborators
National Cancer Institute (NCI) · Janssen, LP
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04030559 on ClinicalTrials.govOther trials for Ataxia-telangiectasia variant
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07224308Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mmThe Levine Center for Plastic Surgery
- ACTIVE NOT RECRUITINGPHASE2NCT06033092Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTionEuropean Institute of Oncology
- RECRUITINGNCT05129605Prostate Cancer Genetic Risk Evaluation and Screening StudyMassachusetts General Hospital